NASDAQ:DRUG Bright Minds Biosciences Q3 2026 Earnings Report $49.21 -0.61 (-1.22%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$46.76 -2.45 (-4.98%) As of 05:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bright Minds Biosciences EPS ResultsActual EPS-$0.17Consensus EPS -$1.22Beat/MissBeat by +$1.05One Year Ago EPSN/ABright Minds Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABright Minds Biosciences Announcement DetailsQuarterQ3 2026Date8/14/2026TimeBefore Market OpensConference Call DateFriday, August 14, 2026Conference Call Time6:20PM ETConference Call ResourcesEarnings HistoryCompany Profile Bright Minds Biosciences Earnings HeadlinesBright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family ConferenceSeptember 30 at 5:30 PM | globenewswire.comBright Minds Biosciences (DRUG) Receives a Rating Update from a Top AnalystSeptember 24, 2026 | theglobeandmail.comThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 2 at 1:00 AM | Investors Alley (Ad)Piper Sandler Sticks to Its Buy Rating for Bright Minds Biosciences (DRUG)September 19, 2026 | theglobeandmail.comBright Minds Biosciences to Present at Upcoming ConferencesSeptember 4, 2026 | globenewswire.comBright Minds: BMB-101 Takes Center Stage Ahead Of Phase 3 Pivotal TrialsAugust 10, 2026 | seekingalpha.comSee More Bright Minds Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bright Minds Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bright Minds Biosciences and other key companies, straight to your email. Email Address About Bright Minds BiosciencesBright Minds Biosciences (NASDAQ:DRUG) is a biotechnology company focused on developing next-generation therapies for neuropsychiatric and neurological disorders. The company’s research centers on selective serotonin receptor agonists designed to address conditions such as treatment-resistant depression, substance use disorders and other disorders involving disrupted brain signaling. Bright Minds’ lead program, BMB-101, is an orally administered, selective 5-HT2C receptor agonist being developed as a potential treatment for conditions including substance use disorder and related neuropsychiatric indications. The company’s drug-development approach is intended to preserve therapeutic effects while reducing some of the adverse effects and limitations associated with less selective psychedelic or serotonergic compounds. Bright Minds Biosciences is based in Vancouver, British Columbia, and conducts biotechnology research and clinical development activities through operations in North America. Its shares trade on the Nasdaq Capital Market under the symbol “DRUG” and on the Canadian Securities Exchange under the same symbol.View Bright Minds Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Micron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket ReachJabil’s Double-Beat and Raise Is a Signal That This Rally Will ContinueMicrosoft's AI Spending Didn't Change—Wall Street's View of It DidL3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
